Thermo Fisher Increases Its Buyout Price for Qiagen, but Investors Ask for More
In one of the biggest deals of 2020, medical equipment giant Thermo Fisher Scientific Inc. (NYSE: TMO) agreed to acquire Qiagen (NYSE: QGEN) in March for $11.5 billion. Qiagen is a diagnostics company focused on analyzing biological samples used for a wide range of applications.
Thermo's deal to acquire Qiagen was straightforward when it was announced, but the two companies have had to come back to the negotiating table as some bumps in the road have emerged.
While the COVID-19 pandemic continues to wreak havoc on the world, Qiagen's business has actually seen its business boom. The company's technology has been found useful for COVID-19 testing, which has led to a significant increase in sales for its equipment and services.
Source Fool.com
